Formulation Development
CordenPharma Increases xRNA-based Capabilities with a Strategic Investment in LNP Formulation Services at its Caponago Injectable Facility
CordenPharma has recently increased its xRNA capabilities at its sterile injectable facility in Caponago, Italy. The company reports that it is investing over €10M in new Lipid Nanoparticle (LNP) formulation,….
BIORESORBABLE POLYMERIC MATRICES - Convergence of Materials Science & Drug Development to Treat Challenging ENT Diseases
Maria Palasis, PhD, and Robert Kern, MD, review how The XTreo platform represents a unique and powerful convergence of materials science, drug development, and formulation chemistry, enabling the local delivery of medication to anatomical spaces not accessible by conventional therapeutic approaches.
EXECUTIVE INTERVIEW - Catalent: Developing & Delivering Billions of Doses of Drugs Every Year
Alessandro Maselli, President and Chief Operating Officer of Catalent, talks about his company’s unique approach to drug development partnerships as he prepares to become the company’s new President and Chief Executive Officer on July 1, 2022.
SYNTHETIC ANTI-INFECTIVES - Synthetic Polymers Offer a New Class of Anti-Infectives
James Graham believes synthetic anti-infectives offer a potential solution to the obstacles encountered by naturally derived antibiotics in the constant arms race against antimicrobial resistance.
Lonza Completes Dedicated Early Clinical Phase Development & Manufacturing Facility in Bend (OR)
Lonza has enhanced its offering for customers in the early phases of their clinical trials by adding a dedicated Early Phase Clinical Manufacturing facility at…
Eagle Pharmaceuticals Announces Submission of NDA to FDA for a Beta-1 Adrenergic Blocker
Eagle Pharmaceuticals, Inc. recently announced that AOP Orphan Pharmaceuticals GmbH, a member of the AOP Health Group, with whom Eagle entered into a licensing agreement…
Denali Therapeutics & Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease
Denali Therapeutics Inc. and Biogen Inc. recently announced that dosing has commenced in the global Phase 2b LUMA study to evaluate the efficacy and safety…
SciSparc to Collaborate With Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems
SciSparc Ltd. recently announced it has signed a collaboration agreement with Polyrizon Ltd., a biotech company focused on the development of innovative medical device hydrogels delivered in….
Agenus Advances Portfolio With 6 Clinical Collaborations
Agenus Inc. recently announced it has entered into three new clinical collaborations with Targovax, Oxford BioTherapeutics, and Immunogenesis, doubling its current number of….
Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the US
Fortress Biotech, Inc. recently announced its subsidiary company, UR-1 Therapeutics, Inc., dosed the first patient in a Phase 1 clinical trial evaluating Dotinurad for the…
Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for the Treatment of Congenital Ichthyosis
Timber Pharmaceuticals, Inc. recently announced the US FDA has granted Breakthrough Therapy designation to TMB-001, a topical isotretinoin formulated using the company’s patented IPEG delivery…
Hepion Pharmaceuticals Highlights Upcoming Phase 2 Clinical Trials of Recofilstat at 5th Global NASH Congress
Hepion Pharmaceuticals, Inc. recently announced that its Chief Medical Officer, Todd Hobbs, MD, gave a clinical presentation titled Recofilstat (CRV431): A liver-targeting drug candidate for…
Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 Demonstrating Encouraging Safety & Efficacy Profile
Purple Biotech Ltd. recently announced positive interim safety and efficacy data from the Phase 1 study of NT219 in adults with advanced solid tumors…..
DFE Pharma Opens New Center of Excellence in India to Provide Fast-Track Formulation Services
DFE Pharma recently announced the launch of its new Center of Excellence Closer to the Formulator (C2F) in Hyderabad, India. The C2F center is based in Genome Valley….
Yingli Pharma Doses First US Patient in Phase 1 Study of YL-13027 for Patients With Advanced Solid Tumors
Yingli Pharma US, Inc. recently announced the first patient has been dosed in its Phase 1 clinical study evaluating YL-13027, a potent and selective TGFβ…
WHITE PAPER: Bring Quality OINDPs to Market Faster Than Ever Before | Proveris Scientific
Learn how the Proveris by Design(TM) approach is a proven tool for successfully developing nasal spray and inhalation drug products….
Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201)
Oncotelic Therapeutics, Inc. recently announced the clearance of the Phase 2 clinical trial protocol for mesothelioma after filing the protocol to the US FDA. Oncotelic…
Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts
Crinetics Pharmaceuticals, Inc. recently announced positive results from the multiple-ascending dose (MAD) portion of a first-in-human Phase 1 clinical study of CRN04894, the company's first-in-class, investigational,…
Pharmazz Inc. Announces Positive Results of Phase 3 Clinical Trial Evaluating Sovateltide as a Treatment for Acute Cerebral Ischemic Stroke
Pharmazz, Inc. recently announced positive topline results of its Phase 3 clinical trial evaluating sovateltide as a treatment for acute ischemic stroke. The data at 90 days showed….
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis
Phathom Pharmaceuticals, Inc. recently announced the US FDA has accepted for review the company’s New Drug Application (NDA) for vonoprazan as a treatment for adults…
